For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

Envivo Pharmaceuticals, Inc.

USPTO Granted Patents = 13

CIPO Patents = 5

EPO Patents = 3

Forward Citations = 76

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Richard Chesworth (12 out of 107 patents)

Gideon Shapiro (12 out of 74 patents)

Amy Ripka (5 out of 28 patents)

4. Gerhard Koenig (2 out of 6 patents)

5. Yves Andre Chantigny (1 out of 7 patents)

6. Patricia Oliver-Shaffer (1 out of 9 patents)

7. Muneki Kishida (1 out of 10 patents)

8. Takayuki Ishige (1 out of 5 patents)

9. Patrick Beaulieu (1 out of 4 patents)

10. Silvana Leit (1 out of 11 patents)

11. John Mancuso (1 out of 3 patents)

12. Pierre Tessier (1 out of 6 patents)

13. David Smil (1 out of 5 patents)

14. Robert Déziel (1 out of 3 patents)

15. Christopher J Cummings (1 out of 2 patents)

13 patents: Sort by Forward Citations

1. 8710227 - Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate (2014-04-29),

2. 8664249 - Tetrasubstituted benzenes (2014-03-04),

3. 8642638 - Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (2014-02-04),

4. 8569354 - Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (2013-10-29),

5. 8481534 - 5- and 6-membered heterocyclic compounds (2013-07-09),

6. 8481532 - PDE-10 inhibitors (2013-07-09),

7. 8466148 - 1,2-disubstituted heterocyclic compounds (2013-06-18),

8. 8399452 - Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors (2013-03-19),

9. 8367863 - Tetrasubstituted benzenes (2013-02-05),

10. 8343973 - Phenoxymethyl heterocyclic compounds (2013-01-01),

11. 8217064 - Tetrasubstituted benzenes (2012-07-10),

12. 8071595 - 1,2-disubstituted heterocyclic compounds (2011-12-06),

13. 7705017 - Compounds for treatment of neurodegenerative diseases (2010-04-27),

EnVivo Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medications for central nervous system disorders. With a mission to improve the lives of patients with conditions such as Alzheimer's disease and schizophrenia, EnVivo is dedicated to advancing innovative therapies. Through their cutting-edge research and development efforts, they aim to deliver important medical solutions to improve mental health and overall well-being.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

13 Patents

#27 in Watertown, MA

#1,400 in Massachusetts

#23,099 in US

#43,615 in the World

Watertown, MA, United States of America

Envivo Pharmaceuticals, Inc.

Forward Citations = 76

24 inventors:

Richard Chesworth (12 out of 107 patents)

Gideon Shapiro (12 out of 74 patents)

Amy Ripka (5 out of 28 patents)

4. Gerhard Koenig (2 out of 6 patents)

5. Yves Andre Chantigny (1 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…